Expanding the KRASG12C Inhibitor Class: What Do We Need Next?

Affiliations

¹ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
² Taussig Cancer Institute, Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio. Electronic address: adjeia2@ccf.org.

Free article

Editorial

Aurora Norman et al. J Thorac Oncol. 2023 Jul.

Free article

. 2023 Jul;18(7):844-846.

doi: 10.1016/j.jtho.2023.04.010.

¹ Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
² Taussig Cancer Institute, Hematology and Medical Oncology, Cleveland Clinic, Cleveland, Ohio. Electronic address: adjeia2@ccf.org.

No abstract available

Comment on

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS^G12C in Patients With NSCLC: Phase 1 Study Results.
Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, Zhou J, Jian H, Dong X, Zhuang W, Cang S, Yang N, Fang J, Shi J, Lu J, Ma R, Wu P, Zhang Y, Song M, Xu CW, Shi Z, Zhang L, Wang Y, Wang X, Zhang Y, Lu S. Li Z, et al. J Thorac Oncol. 2023 Jul;18(7):940-951. doi: 10.1016/j.jtho.2023.03.015. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36948246 Clinical Trial.